{
    "abstract": "Introduction: There is an urgent need for a new and effective tuberculosis vaccine because BCG does not sufficiently prevent pulmonary disease. IMX313 is a novel carrier protein designed to improve cellular and humoral immunity. MVA85A-IMX313 is a novel vaccine candidate designed to boost immunity primed by bacillus Calmette-Gu\u00e9rin (BCG) that has been immunogenic in pre-clinical studies. This is the first evaluation of IMX313 delivered as MVA85A-IMX313 in humans. Methods: In this phase 1, open-label first-in-human trial, 30 healthy previously BCG-vaccinated adults were enrolled into three treatment groups and vaccinated with low dose MVA85A-IMX313 (group A), standard dose MVA85A-IMX313 (group B), or MVA85A (group C). Volunteers were followed up for 6 months for safety and immunogenicity assessment. Results: The majority of adverse events were mild and there were no vaccine-related serious AEs. Both MVA85A-IMX313 and MVA85A induced a significant increase in IFN-\u03b3 ELISpot responses. There were no significant differences between the Ag85A ELISpot and intracellular cytokine responses between the two study groups B (MVA85A-IMX313) and C (MVA85A) at any time point post-vaccination. Conclusion: MVA85A-IMX313 was well tolerated and immunogenic. There was no significant difference in the number of vaccine-related, local or systemic adverse reactions between MVA85A and MVA85A-IMX313 groups. The mycobacteria-specific cellular immune responses induced by MVA85A-IMX313 were not significantly different to those detected in the MVA85A group. In light of this encouraging safety data, further work to improve the potency of molecular adjuvants like IMX313 is merited.This trial was registered on clinicatrials.gov ref. NCT01879163.",
    "bib_entries": {
        "bib0115": null,
        "bib0120": {
            "authors": [
                {
                    "first": "B. Bourdin",
                    "initial": "B.B.",
                    "last": "Trunz"
                },
                {
                    "first": "PEM",
                    "initial": "P.",
                    "last": "Fine"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Dye"
                }
            ],
            "doi": "10.1016/S0140-6736(06)68507-3",
            "firstpage": "1173",
            "issn": "01406736",
            "lastpage": "1180",
            "pmid": "16616560",
            "pub_year": 2006,
            "title": "Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness",
            "volume": "367"
        },
        "bib0125": {
            "authors": [
                {
                    "first": "Laura C.",
                    "initial": "L.C.",
                    "last": "Rodrigues"
                },
                {
                    "first": "Vinod K.",
                    "initial": "V.K.",
                    "last": "Diwan"
                },
                {
                    "first": "Jeremy G.",
                    "initial": "J.G.",
                    "last": "Wheeler"
                }
            ],
            "doi": "10.1093/ije/22.6.1154",
            "firstpage": "1154",
            "issn": "03005771",
            "lastpage": "1158",
            "pmid": "8144299",
            "pub_year": 1993,
            "title": "Protective effect of bcg against tuberculous meningitis and miliary tuberculosis: A meta-analysis",
            "volume": "22"
        },
        "bib0130": {
            "authors": [
                {
                    "first": "P. E.M.",
                    "initial": "P.E.M.",
                    "last": "Fine"
                }
            ],
            "doi": "10.1016/S0140-6736(95)92348-9",
            "firstpage": "1339",
            "issn": "01406736",
            "lastpage": "1345",
            "pmid": "7475776",
            "pub_year": 1995,
            "title": "Variation in protection by BCG: implications of and for heterologous immunity",
            "volume": "346"
        },
        "bib0135": {
            "authors": [
                {
                    "first": "G. A.",
                    "initial": "G.A.",
                    "last": "Colditz"
                },
                {
                    "first": "C. S.",
                    "initial": "C.S.",
                    "last": "Berkey"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Mosteller"
                },
                {
                    "first": "T. F.",
                    "initial": "T.F.",
                    "last": "Brewer"
                },
                {
                    "first": "M. E.",
                    "initial": "M.E.",
                    "last": "Wilson"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Burdick"
                },
                {
                    "first": "H. V.",
                    "initial": "H.V.",
                    "last": "Fineberg"
                }
            ],
            "firstpage": "29",
            "issn": "00314005",
            "lastpage": "35",
            "pmid": "7596718",
            "pub_year": 1995,
            "title": "The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: Meta-analyses of the published literature",
            "volume": "96"
        },
        "bib0140": {
            "authors": [
                {
                    "first": "Solabomi A.",
                    "initial": "S.A.",
                    "last": "Ogun"
                },
                {
                    "first": "Laurence",
                    "initial": "L.",
                    "last": "Dumon-Seignovert"
                },
                {
                    "first": "Jean Baptiste",
                    "initial": "J.B.",
                    "last": "Marchand"
                },
                {
                    "first": "Anthony A.",
                    "initial": "A.A.",
                    "last": "Holder"
                },
                {
                    "first": "Fergal",
                    "initial": "F.",
                    "last": "Hill"
                }
            ],
            "doi": "10.1128/IAI.01369-07",
            "firstpage": "3817",
            "issn": "00199567",
            "lastpage": "3823",
            "pmid": "18474650",
            "pub_year": 2008,
            "title": "The oligomerization domain of C4-binding protein (C4bp) acts as an adjuvant, and the fusion protein comprised of the 19-kilodalton merozoite surface protein 1 fused with the murine C4bp domain protects mice against malaria",
            "volume": "76"
        },
        "bib0145": {
            "authors": [
                {
                    "first": "Hannah B.",
                    "initial": "H.B.",
                    "last": "Ibanga"
                },
                {
                    "first": "Roger H.",
                    "initial": "R.H.",
                    "last": "Brookes"
                },
                {
                    "first": "Philip C.",
                    "initial": "P.C.",
                    "last": "Hill"
                },
                {
                    "first": "Patrick K.",
                    "initial": "P.K.",
                    "last": "Owiafe"
                },
                {
                    "first": "Helen A.",
                    "initial": "H.A.",
                    "last": "Fletcher"
                },
                {
                    "first": "Christian",
                    "initial": "C.",
                    "last": "Lienhardt"
                },
                {
                    "first": "Adrian VS",
                    "initial": "A.V.",
                    "last": "Hill"
                },
                {
                    "first": "Richard A.",
                    "initial": "R.A.",
                    "last": "Adegbola"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "McShane"
                }
            ],
            "doi": "10.1016/S1473-3099(06)70552-7",
            "firstpage": "522",
            "issn": "14733099",
            "lastpage": "528",
            "pmid": "16870530",
            "pub_year": 2006,
            "title": "Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design",
            "volume": "6"
        },
        "bib0150": {
            "authors": [
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "McShane"
                },
                {
                    "first": "Ansar A.",
                    "initial": "A.A.",
                    "last": "Pathan"
                },
                {
                    "first": "Clare R.",
                    "initial": "C.R.",
                    "last": "Sander"
                },
                {
                    "first": "Sheila M.",
                    "initial": "S.M.",
                    "last": "Keating"
                },
                {
                    "first": "Sarah C.",
                    "initial": "S.C.",
                    "last": "Gilbert"
                },
                {
                    "first": "Kris",
                    "initial": "K.",
                    "last": "Huygen"
                },
                {
                    "first": "Helen A.",
                    "initial": "H.A.",
                    "last": "Fletcher"
                },
                {
                    "first": "Adrian V.S.",
                    "initial": "A.V.S.",
                    "last": "Hill"
                }
            ],
            "doi": "10.1038/nm1128",
            "firstpage": "1240",
            "issn": "10788956",
            "lastpage": "1244",
            "pmid": "15502839",
            "pub_year": 2004,
            "title": "Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans",
            "volume": "10"
        },
        "bib0155": {
            "authors": [
                {
                    "first": "Tony",
                    "initial": "T.",
                    "last": "Hawkridge"
                },
                {
                    "first": "Thomas J.",
                    "initial": "T.J.",
                    "last": "Scriba"
                },
                {
                    "first": "Sebastian",
                    "initial": "S.",
                    "last": "Gelderbloem"
                },
                {
                    "first": "Erica",
                    "initial": "E.",
                    "last": "Smit"
                },
                {
                    "first": "Michele",
                    "initial": "M.",
                    "last": "Tameris"
                },
                {
                    "first": "Sizulu",
                    "initial": "S.",
                    "last": "Moyo"
                },
                {
                    "first": "Trudie",
                    "initial": "T.",
                    "last": "Lang"
                },
                {
                    "first": "Ashley",
                    "initial": "A.",
                    "last": "Veldsman"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Hatherill"
                },
                {
                    "first": "Linda",
                    "initial": "L.",
                    "last": "Van Der Merwe"
                },
                {
                    "first": "Helen A.",
                    "initial": "H.A.",
                    "last": "Fletcher"
                },
                {
                    "first": "Hassan",
                    "initial": "H.",
                    "last": "Mahomed"
                },
                {
                    "first": "Adrian V.S.",
                    "initial": "A.V.S.",
                    "last": "Hill"
                },
                {
                    "first": "Willem A.",
                    "initial": "W.A.",
                    "last": "Hanekom"
                },
                {
                    "first": "Gregory D.",
                    "initial": "G.D.",
                    "last": "Hussey"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "McShane"
                }
            ],
            "doi": "10.1086/590185",
            "firstpage": "544",
            "issn": "00221899",
            "lastpage": "552",
            "pmid": "18582195",
            "pub_year": 2008,
            "title": "Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa",
            "volume": "198"
        },
        "bib0160": {
            "authors": [
                {
                    "first": "Michele D.",
                    "initial": "M.D.",
                    "last": "Tameris"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Hatherill"
                },
                {
                    "first": "Bernard S.",
                    "initial": "B.S.",
                    "last": "Landry"
                },
                {
                    "first": "Thomas J.",
                    "initial": "T.J.",
                    "last": "Scriba"
                },
                {
                    "first": "Margaret Ann",
                    "initial": "M.A.",
                    "last": "Snowden"
                },
                {
                    "first": "Stephen",
                    "initial": "S.",
                    "last": "Lockhart"
                },
                {
                    "first": "Jacqueline E.",
                    "initial": "J.E.",
                    "last": "Shea"
                },
                {
                    "first": "J. Bruce",
                    "initial": "J.B.",
                    "last": "McClain"
                },
                {
                    "first": "Gregory D.",
                    "initial": "G.D.",
                    "last": "Hussey"
                },
                {
                    "first": "Willem A.",
                    "initial": "W.A.",
                    "last": "Hanekom"
                },
                {
                    "first": "Hassan",
                    "initial": "H.",
                    "last": "Mahomed"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "McShane"
                }
            ],
            "doi": "10.1016/S0140-6736(13)60177-4",
            "firstpage": "1021",
            "issn": "01406736",
            "lastpage": "1028",
            "pmid": "23391465",
            "pub_year": 2013,
            "title": "Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase 2b trial",
            "volume": "381"
        },
        "bib0165": {
            "authors": [
                {
                    "first": "Alexandra J.",
                    "initial": "A.J.",
                    "last": "Spencer"
                },
                {
                    "first": "Fergal",
                    "initial": "F.",
                    "last": "Hill"
                },
                {
                    "first": "Jared D.",
                    "initial": "J.D.",
                    "last": "Honeycutt"
                },
                {
                    "first": "Matthew G.",
                    "initial": "M.G.",
                    "last": "Cottingham"
                },
                {
                    "first": "Migena",
                    "initial": "M.",
                    "last": "Bregu"
                },
                {
                    "first": "Christine S.",
                    "initial": "C.S.",
                    "last": "Rollier"
                },
                {
                    "first": "Julie",
                    "initial": "J.",
                    "last": "Furze"
                },
                {
                    "first": "Simon J.",
                    "initial": "S.J.",
                    "last": "Draper"
                },
                {
                    "first": "Karen C.",
                    "initial": "K.C.",
                    "last": "S\u00f8gaard"
                },
                {
                    "first": "Sarah C.",
                    "initial": "S.C.",
                    "last": "Gilbert"
                },
                {
                    "first": "David H.",
                    "initial": "D.H.",
                    "last": "Wyllie"
                },
                {
                    "first": "Adrian V.S.",
                    "initial": "A.V.S.",
                    "last": "Hill"
                }
            ],
            "doi": "10.1371/journal.pone.0033555",
            "issn": "19326203",
            "pmid": "22470455",
            "pub_year": 2012,
            "title": "Fusion of the mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates",
            "volume": "7"
        },
        "bib0170": {
            "authors": [
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "McShane"
                },
                {
                    "first": "Ansar A.",
                    "initial": "A.A.",
                    "last": "Pathan"
                },
                {
                    "first": "Clare R.",
                    "initial": "C.R.",
                    "last": "Sander"
                },
                {
                    "first": "Sheila M.",
                    "initial": "S.M.",
                    "last": "Keating"
                },
                {
                    "first": "Sarah C.",
                    "initial": "S.C.",
                    "last": "Gilbert"
                },
                {
                    "first": "Kris",
                    "initial": "K.",
                    "last": "Huygen"
                },
                {
                    "first": "Helen A.",
                    "initial": "H.A.",
                    "last": "Fletcher"
                },
                {
                    "first": "Adrian V.S.",
                    "initial": "A.V.S.",
                    "last": "Hill"
                }
            ],
            "doi": "10.1038/nm1128",
            "firstpage": "1240",
            "issn": "10788956",
            "lastpage": "1244",
            "pmid": "15502839",
            "pub_year": 2004,
            "title": "Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans",
            "volume": "10"
        },
        "bib0175": {
            "authors": [
                {
                    "first": "Joel",
                    "initial": "J.",
                    "last": "Meyer"
                },
                {
                    "first": "Stephanie A.",
                    "initial": "S.A.",
                    "last": "Harris"
                },
                {
                    "first": "Iman",
                    "initial": "I.",
                    "last": "Satti"
                },
                {
                    "first": "Ian D.",
                    "initial": "I.D.",
                    "last": "Poulton"
                },
                {
                    "first": "Hazel C.",
                    "initial": "H.C.",
                    "last": "Poyntz"
                },
                {
                    "first": "Rachel",
                    "initial": "R.",
                    "last": "Tanner"
                },
                {
                    "first": "Rosalind",
                    "initial": "R.",
                    "last": "Rowland"
                },
                {
                    "first": "Kristin L.",
                    "initial": "K.L.",
                    "last": "Griffiths"
                },
                {
                    "first": "Helen A.",
                    "initial": "H.A.",
                    "last": "Fletcher"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "McShane"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.12.042",
            "firstpage": "1026",
            "issn": "0264410X",
            "lastpage": "1033",
            "pmid": "23266342",
            "pub_year": 2013,
            "title": "Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery",
            "volume": "31"
        },
        "bib0180": {
            "authors": [
                {
                    "first": "Willem A.",
                    "initial": "W.A.",
                    "last": "Hanekom"
                },
                {
                    "first": "Jane",
                    "initial": "J.",
                    "last": "Hughes"
                },
                {
                    "first": "Maushumi",
                    "initial": "M.",
                    "last": "Mavinkurve"
                },
                {
                    "first": "Megan",
                    "initial": "M.",
                    "last": "Mendillo"
                },
                {
                    "first": "Marcia",
                    "initial": "M.",
                    "last": "Watkins"
                },
                {
                    "first": "Hoyam",
                    "initial": "H.",
                    "last": "Gamieldien"
                },
                {
                    "first": "Sebastian J.",
                    "initial": "S.J.",
                    "last": "Gelderbloem"
                },
                {
                    "first": "Mzwandile",
                    "initial": "M.",
                    "last": "Sidibana"
                },
                {
                    "first": "Nazma",
                    "initial": "N.",
                    "last": "Mansoor"
                },
                {
                    "first": "Virginia",
                    "initial": "V.",
                    "last": "Davids"
                },
                {
                    "first": "Rose Ann",
                    "initial": "R.A.",
                    "last": "Murray"
                },
                {
                    "first": "Anthony",
                    "initial": "A.",
                    "last": "Hawkridge"
                },
                {
                    "first": "Patrick A.J.",
                    "initial": "P.A.J.",
                    "last": "Haslett"
                },
                {
                    "first": "Stanley",
                    "initial": "S.",
                    "last": "Ress"
                },
                {
                    "first": "Gregory D.",
                    "initial": "G.D.",
                    "last": "Hussey"
                },
                {
                    "first": "Gilla",
                    "initial": "G.",
                    "last": "Kaplan"
                }
            ],
            "doi": "10.1016/j.jim.2004.06.010",
            "firstpage": "185",
            "issn": "00221759",
            "lastpage": "195",
            "pmid": "15345316",
            "pub_year": 2004,
            "title": "Novel application of a whole blood intracellular cytokine detection assay to quantitate specific T-cell frequency in field studies",
            "volume": "291"
        },
        "bib0185": {
            "authors": [
                {
                    "first": "Joel",
                    "initial": "J.",
                    "last": "Meyer"
                },
                {
                    "first": "Stephanie A.",
                    "initial": "S.A.",
                    "last": "Harris"
                },
                {
                    "first": "Iman",
                    "initial": "I.",
                    "last": "Satti"
                },
                {
                    "first": "Ian D.",
                    "initial": "I.D.",
                    "last": "Poulton"
                },
                {
                    "first": "Hazel C.",
                    "initial": "H.C.",
                    "last": "Poyntz"
                },
                {
                    "first": "Rachel",
                    "initial": "R.",
                    "last": "Tanner"
                },
                {
                    "first": "Rosalind",
                    "initial": "R.",
                    "last": "Rowland"
                },
                {
                    "first": "Kristin L.",
                    "initial": "K.L.",
                    "last": "Griffiths"
                },
                {
                    "first": "Helen A.",
                    "initial": "H.A.",
                    "last": "Fletcher"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "McShane"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.12.042",
            "firstpage": "1026",
            "issn": "0264410X",
            "lastpage": "1033",
            "pmid": "23266342",
            "pub_year": 2013,
            "title": "Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery",
            "volume": "31"
        },
        "bib0190": {
            "authors": [
                {
                    "first": "Zhi yong",
                    "initial": "Z.y.",
                    "last": "Yang"
                },
                {
                    "first": "Linda S.",
                    "initial": "L.S.",
                    "last": "Wyatt"
                },
                {
                    "first": "Wing pui",
                    "initial": "W.p.",
                    "last": "Kong"
                },
                {
                    "first": "Zoe",
                    "initial": "Z.",
                    "last": "Moodie"
                },
                {
                    "first": "Bernard",
                    "initial": "B.",
                    "last": "Moss"
                },
                {
                    "first": "Gary J.",
                    "initial": "G.J.",
                    "last": "Nabel"
                }
            ],
            "doi": "10.1128/JVI.77.1.799-803.2003",
            "firstpage": "799",
            "issn": "0022538X",
            "lastpage": "803",
            "pmid": "12477888",
            "pub_year": 2003,
            "title": "Overcoming immunity to a viral vaccine by DNA priming before vector boosting",
            "volume": "77"
        },
        "bib0195": {
            "authors": [
                {
                    "first": "Patricia A.",
                    "initial": "P.A.",
                    "last": "Darrah"
                },
                {
                    "first": "Dipti T.",
                    "initial": "D.T.",
                    "last": "Patel"
                },
                {
                    "first": "Paula M.",
                    "initial": "P.M.",
                    "last": "De Luca"
                },
                {
                    "first": "Ross W.B.",
                    "initial": "R.W.B.",
                    "last": "Lindsay"
                },
                {
                    "first": "Dylan F.",
                    "initial": "D.F.",
                    "last": "Davey"
                },
                {
                    "first": "Barbara J.",
                    "initial": "B.J.",
                    "last": "Flynn"
                },
                {
                    "first": "S\u00f8ren T.",
                    "initial": "S.T.",
                    "last": "Hoff"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Andersen"
                },
                {
                    "first": "Steven G.",
                    "initial": "S.G.",
                    "last": "Reed"
                },
                {
                    "first": "Sheldon L.",
                    "initial": "S.L.",
                    "last": "Morris"
                },
                {
                    "first": "Mario",
                    "initial": "M.",
                    "last": "Roederer"
                },
                {
                    "first": "Robert A.",
                    "initial": "R.A.",
                    "last": "Seder"
                }
            ],
            "doi": "10.1038/nm1592",
            "firstpage": "843",
            "issn": "10788956",
            "lastpage": "850",
            "pmid": "17558415",
            "pub_year": 2007,
            "title": "Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major",
            "volume": "13"
        },
        "bib0200": {
            "authors": [
                {
                    "first": "Robert A.",
                    "initial": "R.A.",
                    "last": "Seder"
                },
                {
                    "first": "Patricia A.",
                    "initial": "P.A.",
                    "last": "Darrah"
                },
                {
                    "first": "Mario",
                    "initial": "M.",
                    "last": "Roederer"
                }
            ],
            "doi": "10.1038/nri2274",
            "firstpage": "247",
            "issn": "14741733",
            "lastpage": "258",
            "pmid": "18323851",
            "pub_year": 2008,
            "title": "T-cell quality in memory and protection: Implications for vaccine design",
            "volume": "8"
        },
        "bib0205": {
            "authors": [
                {
                    "first": "Liliana",
                    "initial": "L.",
                    "last": "Encinales"
                },
                {
                    "first": "Joaquin",
                    "initial": "J.",
                    "last": "Zu\u00f1iga"
                },
                {
                    "first": "Julio",
                    "initial": "J.",
                    "last": "Granados-Montiel"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Yunis"
                },
                {
                    "first": "Julio",
                    "initial": "J.",
                    "last": "Granados"
                },
                {
                    "first": "Ingrid",
                    "initial": "I.",
                    "last": "Almeciga"
                },
                {
                    "first": "Olga",
                    "initial": "O.",
                    "last": "Clavijo"
                },
                {
                    "first": "Carlos",
                    "initial": "C.",
                    "last": "Awad"
                },
                {
                    "first": "Vilma",
                    "initial": "V.",
                    "last": "Collazos"
                },
                {
                    "first": "Mar\u00eda In\u00e9s",
                    "initial": "M.I.",
                    "last": "Vargas-Rojas"
                },
                {
                    "first": "Jos\u00e9 Luis",
                    "initial": "J.L.",
                    "last": "Ba\u00f1ales-Mendez"
                },
                {
                    "first": "Lilia",
                    "initial": "L.",
                    "last": "Vazquez-Casta\u00f1eda"
                },
                {
                    "first": "Joel N.",
                    "initial": "J.N.",
                    "last": "Stern"
                },
                {
                    "first": "Viviana",
                    "initial": "V.",
                    "last": "Romero"
                },
                {
                    "first": "Masha",
                    "initial": "M.",
                    "last": "Frindkis-Hareli"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Terreros"
                },
                {
                    "first": "Marcelo",
                    "initial": "M.",
                    "last": "Fernandez-Vi\u00f1a"
                },
                {
                    "first": "Edmond J.",
                    "initial": "E.J.",
                    "last": "Yunis"
                }
            ],
            "doi": "10.1016/j.molimm.2009.11.005",
            "firstpage": "1066",
            "issn": "01615890",
            "lastpage": "1073",
            "pmid": "20004475",
            "pub_year": 2010,
            "title": "Humoral immunity in tuberculin skin test anergy and its role in high-risk persons exposed to active tuberculosis",
            "volume": "47"
        },
        "bib0210": {
            "authors": [
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Manivannan"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Narayan Rao"
                },
                {
                    "first": "V. D.",
                    "initial": "V.D.",
                    "last": "Ramanathan"
                }
            ],
            "firstpage": "542",
            "issn": "00195189",
            "lastpage": "550",
            "pmid": "23016491",
            "pub_year": 2012,
            "title": "Role of complement activation and antibody in the interaction between Mycobacterium tuberculosis and human macrophages",
            "volume": "50"
        },
        "bib0215": {
            "authors": [
                {
                    "first": "Sergio C.",
                    "initial": "S.C.",
                    "last": "Oliveira"
                },
                {
                    "first": "Gilson C.",
                    "initial": "G.C.",
                    "last": "MacEdo"
                },
                {
                    "first": "Adriana",
                    "initial": "A.",
                    "last": "Bozzi"
                },
                {
                    "first": "Helena Rachel",
                    "initial": "H.R.",
                    "last": "Weinreich"
                },
                {
                    "first": "Andre",
                    "initial": "A.",
                    "last": "Bafica"
                },
                {
                    "first": "Henrique C.",
                    "initial": "H.C.",
                    "last": "Teixeira"
                }
            ],
            "doi": "10.1155/2011/351573",
            "issn": "17402522",
            "pmid": "21253450",
            "pub_year": 2011,
            "title": "Human T cell and antibody-mediated responses to the mycobacterium tuberculosis recombinant 85A, 85B, and ESAT-6 antigens",
            "volume": "2011"
        },
        "bib0220": {
            "authors": [
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Hussain"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Shiratsuchi"
                },
                {
                    "first": "J. J.",
                    "initial": "J.J.",
                    "last": "Ellner"
                },
                {
                    "first": "R. S.",
                    "initial": "R.S.",
                    "last": "Wallis"
                }
            ],
            "firstpage": "449",
            "issn": "00099104",
            "lastpage": "455",
            "pmid": "10691916",
            "pub_year": 2000,
            "title": "PPD-specific IgG1 antibody subclass upregulate tumour necrosis factor expression in PPD-stimulated monocytes: Possible link with disease pathogenesis in tuberculosis",
            "volume": "119"
        }
    },
    "body_text": [
        {
            "endOffset": 42393,
            "parents": [],
            "refoffsets": {
                "bib0190": {
                    "endOffset": 42392,
                    "startOffset": 42388
                }
            },
            "secId": "sec0090",
            "sentence": "It has previously been shown that anti-vector immunity can interfere with insert-induced responses [16].",
            "startOffset": 42289,
            "title": "Discussion"
        },
        {
            "endOffset": 41708,
            "parents": [],
            "secId": "sec0090",
            "sentence": "In this study we show that both MVA85A and MVA85A-IMX313 significantly induce mycobacteria-specific immune responses.",
            "startOffset": 41591,
            "title": "Discussion"
        },
        {
            "endOffset": 19617,
            "parents": [],
            "secId": "sec0005",
            "sentence": "The lack of a safe and effective tuberculosis (TB) vaccine is a public health emergency.",
            "startOffset": 19529,
            "title": "Introduction"
        },
        {
            "endOffset": 34477,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "The volunteer was asymptomatic and the AE was considered possibly related to vaccination.",
            "startOffset": 34388,
            "title": "Vaccine safety"
        },
        {
            "endOffset": 43287,
            "parents": [],
            "secId": "sec0090",
            "sentence": "However, the role of these cells in protection against M.tb remains to be investigated.",
            "startOffset": 43200,
            "title": "Discussion"
        },
        {
            "endOffset": 20096,
            "parents": [],
            "refoffsets": {
                "bib0120": {
                    "endOffset": 20010,
                    "startOffset": 20005
                },
                "bib0125": {
                    "endOffset": 20095,
                    "startOffset": 20090
                },
                "bib0130": {
                    "endOffset": 20095,
                    "startOffset": 20090
                },
                "bib0135": {
                    "endOffset": 20095,
                    "startOffset": 20090
                }
            },
            "secId": "sec0005",
            "sentence": "BCG prevents disseminated disease in childhood [2,3], but does not provide sufficient or consistent protection against pulmonary TB [3\u20135].",
            "startOffset": 19958,
            "title": "Introduction"
        },
        {
            "endOffset": 23134,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "We enrolled volunteers from the general population around Oxford and Birmingham.",
            "startOffset": 23054,
            "title": "Participants"
        },
        {
            "endOffset": 31440,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0050",
            "sentence": "All serum samples from each volunteer were run on the same ELISA plate to control for assay variability.",
            "startOffset": 31336,
            "title": "Antibody Enzyme Linked Immunosorbent assay (ELISA)"
        },
        {
            "endOffset": 25991,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "Volunteers and laboratory staff were blinded to intervention assignment.",
            "startOffset": 25919,
            "title": "Clinical procedures"
        },
        {
            "endOffset": 35192,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0075",
            "sentence": "Significantly increased PPD IFN-\u03b3 responses (median = 447 SFC/106 PBMC) were detected at D7 post-vaccination (data not shown).",
            "startOffset": 35066,
            "title": "MVA85A and MVA85A-IMX313 induces mycobacteria-specific ex vivo IFN-\u03b3 ELISpot responses"
        },
        {
            "endOffset": 43199,
            "parents": [],
            "secId": "sec0090",
            "sentence": "In the present study we could detect vaccine-induced CD4+ T cells that can simultaneously make IFN-\u03b3, TNF-\u03b1 and IL-2 as well as those double positive for IFN-\u03b3 and TNF-\u03b1.",
            "startOffset": 43029,
            "title": "Discussion"
        },
        {
            "endOffset": 23707,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "We enrolled volunteers from the general population around Oxford and Birmingham.",
            "startOffset": 23627,
            "title": "Participants"
        },
        {
            "endOffset": 32007,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0055",
            "sentence": "The Mann\u2013Whitney U-test was used to determine differences between groups.",
            "startOffset": 31934,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 32449,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0055",
            "sentence": "Area Under the curve (AUC) was used to examine overall responses during follow-up period.",
            "startOffset": 32360,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 43693,
            "parents": [],
            "secId": "sec0090",
            "sentence": "The role of humoral immunity is increasingly recognised as important in TB vaccine development.",
            "startOffset": 43598,
            "title": "Discussion"
        },
        {
            "endOffset": 31012,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0050",
            "sentence": "After washing, 100 \u03bcL of optimally diluted (1/1000) anti-human IgG peroxidase conjugate (anti-human IgG1, anti-human IgG2, anti-human IgG3, anti-human IgG4, Fisher Scientific) in FBS-PBS was added to each well.",
            "startOffset": 30802,
            "title": "Antibody Enzyme Linked Immunosorbent assay (ELISA)"
        },
        {
            "endOffset": 21023,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Here we assess the safety and immunogenicity of IMX313 with a clinically advanced candidate TB vaccine \u2013 Modified Vaccinia virus Ankara expressing the immunodominant Mycobacterium.tuberculosis (M.tb) antigen 85A, MVA85A.",
            "startOffset": 20803,
            "title": "Introduction"
        },
        {
            "endOffset": 32054,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0055",
            "sentence": "The secondary study outcome was immunogenicity.",
            "startOffset": 32007,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 43597,
            "parents": [],
            "secId": "sec0090",
            "sentence": "These responses were predominantly IgG1, and the fold change IgG1 responses were higher in the MVA85A-IMX313 group than after MVA85A.",
            "startOffset": 43464,
            "title": "Discussion"
        },
        {
            "endOffset": 30179,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0050",
            "sentence": "Results are presented as fold change in antigen-specific response of IgG (Optical Density OD) from the value at D0.",
            "startOffset": 30064,
            "title": "Antibody Enzyme Linked Immunosorbent assay (ELISA)"
        },
        {
            "endOffset": 24836,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "The first 6 volunteers were assigned to the starter group (group A), who were administered a low dose of MVA85A-IMX313 (1 \u00d7 107 pfu) delivered intradermally in a volume of 150 \u03bcL into the upper arm (all injections were administered by a 29G diameter, 12.7 mm length needle).",
            "startOffset": 24562,
            "title": "Clinical procedures"
        },
        {
            "endOffset": 25554,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "One volunteer (the first group B volunteer) was assigned to receive the higher dose MVA85A-IMX313 (5 \u00d7 107 pfu, delivered intradermally in a volume of 76 \u03bcL) and 48 h after vaccination their safety was reviewed before we proceeded to randomisation of the remaining 23 volunteers.",
            "startOffset": 25275,
            "title": "Clinical procedures"
        },
        {
            "endOffset": 28288,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0040",
            "sentence": "Antigen-specific background subtracted results are presented as spot-forming cells (SFC) per million PBMC.",
            "startOffset": 28182,
            "title": "Ex vivo IFN\u03b3 Enzyme-Linked ImmunoSpot (ELISpot) assay"
        },
        {
            "endOffset": 46075,
            "parents": [],
            "secId": "sec0100",
            "sentence": "The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.",
            "startOffset": 45955,
            "title": "Financial support"
        },
        {
            "endOffset": 23543,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "Latent M.tb infection was excluded by a negative ex vivo IFN-\u03b3 ELISpot response to M.tb early secreted antigenic target 6 kDa (ESAT6) and the 10-kDa culture filtrate protein (CFP10) peptides.",
            "startOffset": 23352,
            "title": "Participants"
        },
        {
            "endOffset": 34387,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "A group C (MVA85A) volunteer had a mildly raised alanine transferase at screening and D7 post-vaccination, which was moderately elevated at D28, mildly elevated at D84 and normalised by D168 post-vaccination.",
            "startOffset": 34179,
            "title": "Vaccine safety"
        },
        {
            "endOffset": 23924,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "They had normal baseline haematology and biochemistry and were hepatitis B, C and HIV negative.",
            "startOffset": 23829,
            "title": "Participants"
        },
        {
            "endOffset": 32245,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0055",
            "sentence": "The Mann\u2013Whitney U-test and unpaired t-test were used to determine differences between groups.",
            "startOffset": 32151,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 21891,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Efforts to improve the immunogenicity of MVA85A are ongoing.",
            "startOffset": 21831,
            "title": "Introduction"
        },
        {
            "endOffset": 35065,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0075",
            "sentence": "At the low dose (107 pfu MVA85A-IMX313) the vaccine induced significant Ag85A-specific IFN-\u03b3 ELISpot responses that peaked at D7 post-vaccination (median = 384 SFC/106 PBMC) and remained significant up to D84 post-vaccination.",
            "startOffset": 34839,
            "title": "MVA85A and MVA85A-IMX313 induces mycobacteria-specific ex vivo IFN-\u03b3 ELISpot responses"
        },
        {
            "endOffset": 24934,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "These group A (low dose MVA85A-IMX313) vaccinations occurred step-wise in order to assess safety.",
            "startOffset": 24837,
            "title": "Clinical procedures"
        },
        {
            "endOffset": 27648,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0040",
            "sentence": "Purified protein derivative (PPD), (Statens Serum Institute, Denmark) was used at 20 \u03bcg/ml.",
            "startOffset": 27557,
            "title": "Ex vivo IFN\u03b3 Enzyme-Linked ImmunoSpot (ELISpot) assay"
        },
        {
            "endOffset": 25756,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "We randomly allocated the remaining 23 eligible volunteers (1:1) to receive intradermal MVA85A-IMX313, 5 \u00d7 107 pfu (Group B) or intradermal MVA85A, 5 \u00d7 107 pfu, delivered in a volume of 60 \u03bcL (Group C).",
            "startOffset": 25554,
            "title": "Clinical procedures"
        },
        {
            "endOffset": 45531,
            "parents": [],
            "secId": "sec0095",
            "sentence": "This research may have the potential to accelerate not only TB vaccine development, but also that of other pathogens of global importance including HIV, influenza, Staphylococcus aureus and malaria.",
            "startOffset": 45333,
            "title": "Conclusion"
        },
        {
            "endOffset": 31336,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0050",
            "sentence": "Results are presented as fold change in OD from the value at Day 0.",
            "startOffset": 31269,
            "title": "Antibody Enzyme Linked Immunosorbent assay (ELISA)"
        },
        {
            "endOffset": 42540,
            "parents": [],
            "secId": "sec0090",
            "sentence": "We studied vaccine-induced cellular anti-vector immunity and demonstrated that both studied vaccines induced comparable anti-MVA T cell responses.",
            "startOffset": 42394,
            "title": "Discussion"
        },
        {
            "endOffset": 33637,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "There was no statistical difference between group B and group C with p values of 0.1236 (redness) and 0.6430 (swelling) (Fig. 2).",
            "startOffset": 33508,
            "title": "Vaccine safety"
        },
        {
            "endOffset": 34723,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "There were no other serious AEs.",
            "startOffset": 34691,
            "title": "Vaccine safety"
        },
        {
            "endOffset": 20704,
            "parents": [],
            "refoffsets": {
                "bib0140": {
                    "endOffset": 20703,
                    "startOffset": 20700
                }
            },
            "secId": "sec0005",
            "sentence": "The 55 amino acid sequence is a hybrid of the oligomerisation domains of two chicken C4b-binding proteins, both distant homologues of human Complement 4 binding protein (C4bp) [6].",
            "startOffset": 20524,
            "title": "Introduction"
        },
        {
            "endOffset": 32982,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "The numbers of AEs considered at least possibly related to vaccination were broadly similar between groups with medians of 10 in group A (low dose MVA85A-IMX313), 8.5 in group B (MVA85A-IMX313) and 9 in group C (MVA85A).",
            "startOffset": 32762,
            "title": "Vaccine safety"
        },
        {
            "endOffset": 38068,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0080",
            "sentence": "A significant increase in percentages of CD4+ T cells producing TNF-\u03b1 was detected in group C (MVA85A) at D168 (Fig. 4B).",
            "startOffset": 37947,
            "title": "Total whole blood intracellular cytokine response"
        },
        {
            "endOffset": 45767,
            "parents": [],
            "secId": "sec0100",
            "sentence": "An Aeras grant to Oxford (MCA002) funded the Clinical Research Fellow post.",
            "startOffset": 45692,
            "title": "Financial support"
        },
        {
            "endOffset": 45954,
            "parents": [],
            "secId": "sec0100",
            "sentence": "The research was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre based at Oxford University Hospitals NHS Trust and University of Oxford.",
            "startOffset": 45768,
            "title": "Financial support"
        },
        {
            "endOffset": 21946,
            "parents": [],
            "secId": "sec0005",
            "sentence": "In one strategy, MVA85A has been combined with IMX313.",
            "startOffset": 21892,
            "title": "Introduction"
        },
        {
            "endOffset": 23255,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "Volunteers were healthy, aged between 18 and 55 and had received BCG at least 6 months prior to their date of enrolment.",
            "startOffset": 23135,
            "title": "Participants"
        },
        {
            "endOffset": 27737,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0040",
            "sentence": "ELISpot plates (Millipore) were coated with capture mAb then incubated overnight at 4 \u00b0C.",
            "startOffset": 27648,
            "title": "Ex vivo IFN\u03b3 Enzyme-Linked ImmunoSpot (ELISpot) assay"
        },
        {
            "endOffset": 37005,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0075",
            "sentence": "Vaccination with MVA85A-IMX313 or MVA85A alone did not induce ELISpot responses to IMX313 or C4bp peptides (Supplementary Material 1).",
            "startOffset": 36871,
            "title": "MVA85A and MVA85A-IMX313 induces mycobacteria-specific ex vivo IFN-\u03b3 ELISpot responses"
        },
        {
            "endOffset": 25918,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "Randomisation was done with sequentially numbered, opaque, sealed envelopes, prepared by an independent statistician, opened by the study clinician at enrolment.",
            "startOffset": 25757,
            "title": "Clinical procedures"
        },
        {
            "endOffset": 40212,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0085",
            "sentence": "Group B median OD 405 nm fold change was 3.966 at D14 and 4.506 at D28 compared to group C median OD 405 nm fold change of 2.347 at D14 and 2.891 at D28.",
            "startOffset": 40059,
            "title": "Serum IgG responses after MVA85A-IMX313 and MVA85A vaccination"
        },
        {
            "endOffset": 26453,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "Symptoms were reviewed at each clinic visit, and vaccination site observations (redness, swelling) and vital signs (blood pressure, heart rate, oral or tympanic temperature) were recorded.",
            "startOffset": 26265,
            "title": "Clinical procedures"
        },
        {
            "endOffset": 44673,
            "parents": [],
            "refoffsets": {
                "bib0165": {
                    "endOffset": 44672,
                    "startOffset": 44668
                }
            },
            "secId": "sec0090",
            "sentence": "No antibody cross-reactivity was detected in any of the study groups to the oligomerisation domain of human C4bp, which is likely due to the limited similarity between the IMX313 and human C4bp [11].",
            "startOffset": 44474,
            "title": "Discussion"
        },
        {
            "endOffset": 33958,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "The group B (MVA85A-IMX313) volunteer reported severe nausea from D2 to D3, severe malaise from D2 to D4 and severe fatigue from D2 to D4 following vaccination.",
            "startOffset": 33798,
            "title": "Vaccine safety"
        },
        {
            "endOffset": 23039,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "This trial was registered on clinicatrials.gov (ref. NCT01879163) and was conducted according to the principles of the Declaration of Helsinki and Good Clinical Practice.",
            "startOffset": 22869,
            "title": "Study design"
        },
        {
            "endOffset": 32581,
            "parents": [],
            "secId": "sec0060",
            "sentence": "Between July 17 2013 and July 17 2014, 30 of the 42 volunteers screened for eligibility were enrolled in the trial (Fig. 1).",
            "startOffset": 32457,
            "title": "Results"
        },
        {
            "endOffset": 39530,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0085",
            "sentence": "MVA85A-IMX313 vaccination induced a median OD 405 nm fold change of 1.640 in group B volunteers and MVA85A vaccination induced a median OD 405 nm fold change of 1.227 in group C volunteers (Fig. 6A).",
            "startOffset": 39331,
            "title": "Serum IgG responses after MVA85A-IMX313 and MVA85A vaccination"
        },
        {
            "endOffset": 34690,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "There was one unrelated serious AE reported in the study in a group B (MVA85A-IMX313) volunteer who was admitted overnight to hospital for investigation of chest pain 157 days after vaccination with MVA85A-IMX313.",
            "startOffset": 34477,
            "title": "Vaccine safety"
        },
        {
            "endOffset": 24423,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "bib0165": {
                    "endOffset": 24422,
                    "startOffset": 24418
                }
            },
            "secId": "sec0025",
            "sentence": "MVA85A-IMX313 (lot number 0010812), which expresses the IMX313 fusion protein, was constructed as described elsewhere [11].",
            "startOffset": 24300,
            "title": "Vaccines"
        },
        {
            "endOffset": 42019,
            "parents": [],
            "refoffsets": {
                "bib0165": {
                    "endOffset": 42018,
                    "startOffset": 42014
                }
            },
            "secId": "sec0090",
            "sentence": "This finding is in contrast with previously published data comparing the same vaccines in animal models, where MVA85A-IMX313 was more immunogenic than MVA85A [11].",
            "startOffset": 41856,
            "title": "Discussion"
        },
        {
            "endOffset": 42933,
            "parents": [],
            "refoffsets": {
                "bib0195": {
                    "endOffset": 42932,
                    "startOffset": 42925
                },
                "bib0200": {
                    "endOffset": 42932,
                    "startOffset": 42925
                }
            },
            "secId": "sec0090",
            "sentence": "While there are no defined correlates of protection against TB, work on a Leishmania major pre-clinical model has demonstrated the importance of the quality of vaccine-induced T cells as measured by cytokines polyfunctionality in protection [17,18].",
            "startOffset": 42684,
            "title": "Discussion"
        },
        {
            "endOffset": 41591,
            "parents": [],
            "secId": "sec0090",
            "sentence": "These AEs were included in the analysis because it was not possible to fully distinguish symptoms that were potentially related to the vaccine from symptoms arising from the volunteer's probably infectious pathology.",
            "startOffset": 41375,
            "title": "Discussion"
        },
        {
            "endOffset": 32761,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "Group A (the low dose MVA85A-IMX313 safety group) proceeded to completion without safety concerns.",
            "startOffset": 32663,
            "title": "Vaccine safety"
        },
        {
            "endOffset": 37139,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0075",
            "sentence": "Vaccination with MVA85A-IMX313 or MVA85A alone did not induce ELISpot responses to IMX313 or C4bp peptides (Supplementary Material 1).",
            "startOffset": 37005,
            "title": "MVA85A and MVA85A-IMX313 induces mycobacteria-specific ex vivo IFN-\u03b3 ELISpot responses"
        },
        {
            "endOffset": 38469,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0080",
            "sentence": "CD8+ T cells producing IFN-\u03b3 and TNF-\u03b1 were detected at very low percentages in both groups B (median D7 responses of 0.006 and 0.005 for CD8+IFN-\u03b3+ and CD8+TNF-\u03b1+ respectively) and C (median D7 responses of 0.003 and 0.0027 for CD8+IFN-\u03b3+ and CD8+TNF-\u03b1+ respectively) (data not shown).",
            "startOffset": 38183,
            "title": "Total whole blood intracellular cytokine response"
        },
        {
            "endOffset": 21284,
            "parents": [],
            "refoffsets": {
                "bib0145": {
                    "endOffset": 21283,
                    "startOffset": 21278
                },
                "bib0150": {
                    "endOffset": 21283,
                    "startOffset": 21278
                },
                "bib0155": {
                    "endOffset": 21283,
                    "startOffset": 21278
                }
            },
            "secId": "sec0005",
            "sentence": "In phase I trials, MVA85A was highly immunogenic and induced potent Ag85A specific CD4+ T-cell responses in BCG-vaccinated adults [7\u20139].",
            "startOffset": 21148,
            "title": "Introduction"
        },
        {
            "endOffset": 31268,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0050",
            "sentence": "The reaction was stopped after 20 min with 2 N H2SO4, and OD values were read at 405 nm.",
            "startOffset": 31180,
            "title": "Antibody Enzyme Linked Immunosorbent assay (ELISA)"
        },
        {
            "endOffset": 33192,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "There were no documented temperature rises following vaccination in any group.",
            "startOffset": 33114,
            "title": "Vaccine safety"
        },
        {
            "endOffset": 24116,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "Latent M.tb infection was excluded by a negative ex vivo IFN-\u03b3 ELISpot response to M.tb early secreted antigenic target 6 kDa (ESAT6) and the 10-kDa culture filtrate protein (CFP10) peptides.",
            "startOffset": 23925,
            "title": "Participants"
        },
        {
            "endOffset": 30566,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0050",
            "sentence": "The wells of ELISA plates (Nunc) were sensitised with Ag85A, IMX313 and hC4bp proteins (100 \u03bcL/well in carbonate buffer pH 9.6 at 4 \u00b0C, overnight), followed by blocking with 10% bovine foetal serum (non-USA origin, sterile-filtered, Sigma) in PBS (pH 7.4) for 2 h at room temperature.",
            "startOffset": 30282,
            "title": "Antibody Enzyme Linked Immunosorbent assay (ELISA)"
        },
        {
            "endOffset": 33113,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "All related AEs and their severities are shown in Table 2.",
            "startOffset": 33055,
            "title": "Vaccine safety"
        },
        {
            "endOffset": 29316,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0045",
            "sentence": "Cytokines were measured in singlet CD14\u2212CD19\u2212CD3+, CD4+ or CD8+ T cells.",
            "startOffset": 29244,
            "title": "Whole Blood (WB) Intracellular Cytokine Staining (ICS)"
        },
        {
            "endOffset": 36172,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0075",
            "sentence": "The PPD response was not significantly different between the MVA85A-IMX313 and MVA85A groups (AUC, p = 0.5059).",
            "startOffset": 36061,
            "title": "MVA85A and MVA85A-IMX313 induces mycobacteria-specific ex vivo IFN-\u03b3 ELISpot responses"
        },
        {
            "endOffset": 39266,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0085",
            "sentence": "Levels of serum IgG were assessed in volunteers in the MVA85A-IMX313 and MVA85A (both at 5 \u00d7 107 pfu) study groups.",
            "startOffset": 39151,
            "title": "Serum IgG responses after MVA85A-IMX313 and MVA85A vaccination"
        },
        {
            "endOffset": 29880,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0050",
            "sentence": "Insert-specific IgG responses were measured to recombinant Ag85A (Lionex, Germany).",
            "startOffset": 29797,
            "title": "Antibody Enzyme Linked Immunosorbent assay (ELISA)"
        },
        {
            "endOffset": 33507,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "There was no significant difference in the local injection site reaction between groups, with median diameters of redness and swelling of 28.5 mm and 9 mm in group A (low dose MVA85A-IMX313), 40 mm and 11.5 mm in group B (MVA-IMX313) and 32 mm and 14 mm in group C (MVA85A).",
            "startOffset": 33233,
            "title": "Vaccine safety"
        },
        {
            "endOffset": 28819,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0045",
            "sentence": "Samples were then treated with 2 mM EDTA (GIBCO).",
            "startOffset": 28770,
            "title": "Whole Blood (WB) Intracellular Cytokine Staining (ICS)"
        },
        {
            "endOffset": 36871,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0075",
            "sentence": "There were no significant differences in responses to MVA epitopes between the two study groups (AUC, p = 0.2721 and p = 0.1585 for MVA CD4+ T cells epitopes and MVA CD8+ T cells epitopes respectively) (Fig. 3D).",
            "startOffset": 36659,
            "title": "MVA85A and MVA85A-IMX313 induces mycobacteria-specific ex vivo IFN-\u03b3 ELISpot responses"
        },
        {
            "endOffset": 39806,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0085",
            "sentence": "When individual IgG subclasses were examined, in both groups IgG1 responses to Ag85A increased at D28 post-vaccination in both groups (median OD 405 nm fold change = 2.19 and 1.83 in group B and C, respectively).",
            "startOffset": 39594,
            "title": "Serum IgG responses after MVA85A-IMX313 and MVA85A vaccination"
        },
        {
            "endOffset": 39985,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0085",
            "sentence": "Other 85A-specific IgG subclasses responses did were not induced (Fig. 7A).",
            "startOffset": 39910,
            "title": "Serum IgG responses after MVA85A-IMX313 and MVA85A vaccination"
        },
        {
            "endOffset": 44473,
            "parents": [],
            "secId": "sec0090",
            "sentence": "The role of these antibody responses is unclear and needs to be further investigated.",
            "startOffset": 44388,
            "title": "Discussion"
        },
        {
            "endOffset": 38182,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0080",
            "sentence": "Ag85A-specific IL-17+ CD4+ T cell responses were detectable following vaccination in both study groups (Fig. 4D).",
            "startOffset": 38069,
            "title": "Total whole blood intracellular cytokine response"
        },
        {
            "endOffset": 45105,
            "parents": [],
            "secId": "sec0090",
            "sentence": "These approaches include the inclusion of technologies to enhance immunogenicity, novel antigen delivery systems that induce different phenotypes of T cells, novel routes of immunisation and the assessment of novel candidate antigens.",
            "startOffset": 44871,
            "title": "Discussion"
        },
        {
            "endOffset": 36060,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0075",
            "sentence": "There was a significant increase in PPD-specific IFN-\u03b3 ELISpot responses in both groups at D7 in comparison to baseline with a median IFN-\u03b3 response of 542.5 SFC/106 PBMC in group B (MVA85A-IMX313) and 780 SFC/106 PBMC in group C (MVA85A) (Fig. 3B).",
            "startOffset": 35811,
            "title": "MVA85A and MVA85A-IMX313 induces mycobacteria-specific ex vivo IFN-\u03b3 ELISpot responses"
        },
        {
            "endOffset": 44188,
            "parents": [],
            "refoffsets": {
                "bib0220": {
                    "endOffset": 44187,
                    "startOffset": 44183
                }
            },
            "secId": "sec0090",
            "sentence": "It was suggested that the presence of IgG1 and IgG3 antibodies might enhance bacterial uptake and clearance of pathogen via macrophages Fc receptor [22].",
            "startOffset": 44035,
            "title": "Discussion"
        },
        {
            "endOffset": 40783,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0085",
            "sentence": "There were no detectable responses to human C4bp at any time point post-vaccination (Fig. 6D).",
            "startOffset": 40689,
            "title": "Serum IgG responses after MVA85A-IMX313 and MVA85A vaccination"
        },
        {
            "endOffset": 43933,
            "parents": [],
            "refoffsets": {
                "bib0215": {
                    "endOffset": 43932,
                    "startOffset": 43928
                }
            },
            "secId": "sec0090",
            "sentence": "IgG1 was reported to be the predominant antibody Isotype present in sera of TB Patients [21].",
            "startOffset": 43840,
            "title": "Discussion"
        },
        {
            "endOffset": 28443,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "refoffsets": {
                "bib0180": {
                    "endOffset": 28442,
                    "startOffset": 28438
                }
            },
            "secId": "sec0045",
            "sentence": "Ag85A-specific intracellular cytokines were measured in WB samples as previously described [14].",
            "startOffset": 28347,
            "title": "Whole Blood (WB) Intracellular Cytokine Staining (ICS)"
        },
        {
            "endOffset": 45691,
            "parents": [],
            "secId": "sec0100",
            "sentence": "A Wellcome Trust Senior Clinical Research Fellowship (Helen McShane; 095780/Z/11/Z) and a financial contribution from IMAXIO funded this trial.",
            "startOffset": 45548,
            "title": "Financial support"
        },
        {
            "endOffset": 31933,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0055",
            "sentence": "Statistical analyses to compare the standard dose groups were performed using GraphPad Prism.",
            "startOffset": 31840,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 24299,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "bib0170": {
                    "endOffset": 24298,
                    "startOffset": 24294
                }
            },
            "secId": "sec0025",
            "sentence": "Clinical-grade MVA85A (lot number 0050811) was constructed as previously described [12].",
            "startOffset": 24211,
            "title": "Vaccines"
        },
        {
            "endOffset": 34116,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "The volunteer from group C (MVA85A) had vaccination site swelling that met the criteria for a severe AE that peaked at 60 mm diameter on D4 post-vaccination.",
            "startOffset": 33959,
            "title": "Vaccine safety"
        },
        {
            "endOffset": 35583,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0075",
            "sentence": "These responses peaked at D7 post-vaccination with a median IFN-\u03b3 response of 515 SFC/106 PBMC in the MVA85A-IMX313 group compared to 1107.5 SFC/106 PBMC in the MVA85A group (Fig. 3A).",
            "startOffset": 35399,
            "title": "MVA85A and MVA85A-IMX313 induces mycobacteria-specific ex vivo IFN-\u03b3 ELISpot responses"
        },
        {
            "endOffset": 39038,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0080",
            "sentence": "The magnitude of these responses was not significantly different between the two study groups (AUC p = 0.863 and p = 0.518 for CD4+ T cells simultaneously producing IFN-\u03b3, TNF-\u03b1 or double positive for IFN-\u03b3 and TNF-\u03b1 respectively (Mann\u2013Whitney)) (Fig. 5).",
            "startOffset": 38783,
            "title": "Total whole blood intracellular cytokine response"
        },
        {
            "endOffset": 40946,
            "parents": [],
            "secId": "sec0090",
            "sentence": "In this phase I clinical trial we assessed the safety and adjuvant effect of IMX313, which was delivered for the first time to humans, as MVA85A-IMX313.",
            "startOffset": 40794,
            "title": "Discussion"
        },
        {
            "endOffset": 44034,
            "parents": [],
            "refoffsets": {
                "bib0220": {
                    "endOffset": 43953,
                    "startOffset": 43949
                }
            },
            "secId": "sec0090",
            "sentence": "Hussein et al. [22] suggested a role of IgG1 in TB by enhancing release of TNF-\u03b1 in active patients.",
            "startOffset": 43934,
            "title": "Discussion"
        },
        {
            "endOffset": 36658,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0075",
            "sentence": "ELISpot responses to MVA CD8+ T cell epitopes were significantly induced in both groups and these responses also peaked at D14 with a median response of 117 SFC/106 PBMC in group B (MVA85A-IMX313) and 282 SFC/106 PBMC in group C (MVA85A), remaining significantly increased until D28.",
            "startOffset": 36375,
            "title": "MVA85A and MVA85A-IMX313 induces mycobacteria-specific ex vivo IFN-\u03b3 ELISpot responses"
        },
        {
            "endOffset": 38782,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0080",
            "sentence": "We focussed on the dominant functional phenotypes and found polyfunctional CD4+ T cells, making two or more cytokines simultaneously, cells producing IFN-\u03b3 in combination with TNF-\u03b1 and IL-2 (Fig. 5A) or double positive for IFN-\u03b3 and TNF-\u03b1 (Fig. 5B) were all induced following MVA85A-IMX313 or MVA85A vaccination.",
            "startOffset": 38469,
            "title": "Total whole blood intracellular cytokine response"
        },
        {
            "endOffset": 44387,
            "parents": [],
            "secId": "sec0090",
            "sentence": "In this trial, both vaccine groups had a comparable increase in serum MVA-specific IgG, while IgG responses to IMX313 increased in the MVA85A-IMX313 group and were not detectable in the MVA85A group.",
            "startOffset": 44188,
            "title": "Discussion"
        },
        {
            "endOffset": 33797,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "There were four severe AEs that were considered possibly related to vaccination (3 in a group B, MVA85A-IMX313 volunteer and 1 in a group C, MVA85A volunteer).",
            "startOffset": 33638,
            "title": "Vaccine safety"
        },
        {
            "endOffset": 37717,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0080",
            "sentence": "No significant differences in percentages of cells producing IFN-\u03b3, TNF-\u03b1, IL-2 and IL-17 were detected between the two groups (AUC, p = 0.4799, p = 0.5987, p = 0.5575, p = 0.3241, p = 0.6943 and p = 0.8325 for CD4+ T cells IFN-\u03b3, TNF-\u03b1, IL-2 and IL-17 and CD8+ T cells IFN-\u03b3 and TNF-\u03b1, respectively) (Fig. 4).",
            "startOffset": 37407,
            "title": "Total whole blood intracellular cytokine response"
        },
        {
            "endOffset": 21147,
            "parents": [],
            "secId": "sec0005",
            "sentence": "MVA85A was designed to boost BCG induced protection and is the only TB subunit vaccine to be evaluated in an efficacy trial.",
            "startOffset": 21023,
            "title": "Introduction"
        },
        {
            "endOffset": 30725,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0050",
            "sentence": "Plates were washed twice with PBS containing 0.05% Tween 20 (PBS/T), followed by addition of 100 \u03bcL/well of optimally diluted sera (1/50), in duplicate wells.",
            "startOffset": 30567,
            "title": "Antibody Enzyme Linked Immunosorbent assay (ELISA)"
        },
        {
            "endOffset": 43839,
            "parents": [],
            "refoffsets": {
                "bib0205": {
                    "endOffset": 43833,
                    "startOffset": 43829
                },
                "bib0210": {
                    "endOffset": 43838,
                    "startOffset": 43834
                }
            },
            "secId": "sec0090",
            "sentence": "It was previously shown that mycobacteria-specific human IgG could modulate both cellular and humoral immune responses to mycobacteria [19] [20].",
            "startOffset": 43694,
            "title": "Discussion"
        },
        {
            "endOffset": 29192,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0045",
            "sentence": "Stimulated and fixed WB samples were permeabilised and incubated with antibodies against: CD3 (AF700), IFN-\u03b3 (PE-Cy7) (Ebioscience), CD4 (Pacific Blue), TNF-\u03b1 (APC), IL-17 (AF488) (Biolegend), CD14 and CD19 (ECD), IL-2 (PE) (Beckman Coulter) and CD8 (APC-H7) (BD).",
            "startOffset": 28928,
            "title": "Whole Blood (WB) Intracellular Cytokine Staining (ICS)"
        },
        {
            "endOffset": 39593,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0085",
            "sentence": "These responses were not different between groups (p = 0.343).",
            "startOffset": 39531,
            "title": "Serum IgG responses after MVA85A-IMX313 and MVA85A vaccination"
        },
        {
            "endOffset": 41163,
            "parents": [],
            "secId": "sec0090",
            "sentence": "Importantly, there were no documented high temperatures in any volunteers.",
            "startOffset": 41089,
            "title": "Discussion"
        },
        {
            "endOffset": 26835,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "Solicited (local injection site: pain, redness, swelling, warmth, itch, scaling; and systemic: documented fever, feverishness, malaise, arthralgia, headache, myalgia, nausea/vomiting, fatigue) and unsolicited AEs were recorded in line-listings for later analysis.",
            "startOffset": 26572,
            "title": "Clinical procedures"
        },
        {
            "endOffset": 23627,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "The full inclusion and exclusion criteria are described in Supplementary Methods 1.",
            "startOffset": 23544,
            "title": "Participants"
        },
        {
            "endOffset": 22240,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Here we describe the first clinical evaluation of IMX313, administered as MVA85A-IMX313, and compared the safety and immunogenicity profile with MVA85A in a phase I trial in BCG-vaccinated UK adults.",
            "startOffset": 22041,
            "title": "Introduction"
        },
        {
            "endOffset": 29796,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "refoffsets": {
                "bib0185": {
                    "endOffset": 29795,
                    "startOffset": 29791
                }
            },
            "secId": "sec0050",
            "sentence": "Levels of Immunoglobulin G (IgG) were measured in serum samples collected on days 0, 14 and 28 as previously described [15].",
            "startOffset": 29672,
            "title": "Antibody Enzyme Linked Immunosorbent assay (ELISA)"
        },
        {
            "endOffset": 42090,
            "parents": [],
            "secId": "sec0090",
            "sentence": "This may be due to differences in vaccine regime, dose and/or species.",
            "startOffset": 42020,
            "title": "Discussion"
        },
        {
            "endOffset": 43028,
            "parents": [],
            "secId": "sec0090",
            "sentence": "A successful vaccine against TB, might require the induction of potent polyfunctional T cells.",
            "startOffset": 42934,
            "title": "Discussion"
        },
        {
            "endOffset": 20200,
            "parents": [],
            "secId": "sec0005",
            "sentence": "It confers varying effectiveness across different populations for reasons that are not well understood.",
            "startOffset": 20097,
            "title": "Introduction"
        },
        {
            "endOffset": 42683,
            "parents": [],
            "secId": "sec0090",
            "sentence": "Intracellular whole blood cytokines were comparable between the two study groups and polyfunctional CD4+ T cells were induced by both vaccines.",
            "startOffset": 42540,
            "title": "Discussion"
        },
        {
            "endOffset": 36374,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0075",
            "sentence": "ELISpot IFN-\u03b3 responses to MVA CD4+ T cell epitopes peaked at D14 post-vaccination, with median responses of 19 SFC/106 PBMC in group B (MVA85A-IMX313) and 31 SFC/106 PBMC in group C (MVA85A) (Fig. 3C).",
            "startOffset": 36172,
            "title": "MVA85A and MVA85A-IMX313 induces mycobacteria-specific ex vivo IFN-\u03b3 ELISpot responses"
        },
        {
            "endOffset": 40472,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0085",
            "sentence": "IMX313-specific IgG responses were detectable in the MVA85A-IMX313 vaccination group (B) at D14 post-vaccination and significantly increased at D28 (p = 0.0028).",
            "startOffset": 40311,
            "title": "Serum IgG responses after MVA85A-IMX313 and MVA85A vaccination"
        },
        {
            "endOffset": 23828,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "Volunteers were healthy, aged between 18 and 55 and had received BCG at least 6 months prior to their date of enrolment.",
            "startOffset": 23708,
            "title": "Participants"
        },
        {
            "endOffset": 39330,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0085",
            "sentence": "There was an increase in serum Ag85A-IgG at D28 in both groups.",
            "startOffset": 39267,
            "title": "Serum IgG responses after MVA85A-IMX313 and MVA85A vaccination"
        },
        {
            "endOffset": 23351,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "They had normal baseline haematology and biochemistry and were hepatitis B, C and HIV negative.",
            "startOffset": 23256,
            "title": "Participants"
        },
        {
            "endOffset": 26264,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "Volunteers completed diary-cards for the recording of adverse events (AEs) for 7 days post-vaccination.",
            "startOffset": 26161,
            "title": "Clinical procedures"
        },
        {
            "endOffset": 21831,
            "parents": [],
            "refoffsets": {
                "bib0155": {
                    "endOffset": 21830,
                    "startOffset": 21827
                }
            },
            "secId": "sec0005",
            "sentence": "After vaccination with MVA85A there was only a modest induction of Th1 and Th17 antigen specific T-cell responses, which was 10-fold lower than that seen in UK adults [9].",
            "startOffset": 21660,
            "title": "Introduction"
        },
        {
            "endOffset": 19740,
            "parents": [],
            "refoffsets": {
                "bib0115": {
                    "endOffset": 19739,
                    "startOffset": 19736
                }
            },
            "secId": "sec0005",
            "sentence": "TB causes a major global health burden, with an estimated 9.0 million incident cases and 1.5 million deaths each year [1].",
            "startOffset": 19618,
            "title": "Introduction"
        },
        {
            "endOffset": 40688,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0085",
            "sentence": "When IgG subclasses were examined, the IMX313-specific IgG responses in the MVA85A-IMX313 Group (B) were mainly IgG1 (Fig. 7B).",
            "startOffset": 40561,
            "title": "Serum IgG responses after MVA85A-IMX313 and MVA85A vaccination"
        },
        {
            "endOffset": 37946,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0080",
            "sentence": "Group B (MVA85A-IMX313) volunteers had significantly higher percentages of CD4+ TNF-\u03b1+ T cells at D7 and D168 compared to baseline.",
            "startOffset": 37815,
            "title": "Total whole blood intracellular cytokine response"
        },
        {
            "endOffset": 22707,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "We enrolled volunteers following their written informed consent under a protocol approved by the UK Medicines and Healthcare products Regulatory Agency (EudraCT 2013-000678-31) and the NRES South Central \u2013 Oxford Research Ethics Committee (ref. 13/SC/0207).",
            "startOffset": 22450,
            "title": "Study design"
        },
        {
            "endOffset": 28059,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0040",
            "sentence": "3 \u00d7 105 PBMC were incubated for 18\u201320 h at 37 \u00b0C/5% CO2 with Ag85A (single pool of 66 15mer peptides, overlapping by 10 amino acids) (PPR, UK), purified protein derivative (PPD) (Staten Serum Institute, Denmark), MVA CD4 and CD8T cell epitopes (PPR, UK), IMX313 (IMAXIO, France) and hC4bp (provided by Anna Blom, Sweden).",
            "startOffset": 27738,
            "title": "Ex vivo IFN\u03b3 Enzyme-Linked ImmunoSpot (ELISpot) assay"
        },
        {
            "endOffset": 37814,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0080",
            "sentence": "CD4+ T cell IFN-\u03b3 and IL-2 significantly increased in both groups at D7 and D168 (Fig. 4A and C).",
            "startOffset": 37717,
            "title": "Total whole blood intracellular cytokine response"
        },
        {
            "endOffset": 19845,
            "parents": [],
            "secId": "sec0005",
            "sentence": "In addition, the emergence of drug resistant forms of TB further magnifies the difficulty of TB control.",
            "startOffset": 19741,
            "title": "Introduction"
        },
        {
            "endOffset": 28928,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0045",
            "sentence": "Red blood cells were lysed using FACS Lysing solution (BD) and samples were frozen for batched ICS analysis.",
            "startOffset": 28820,
            "title": "Whole Blood (WB) Intracellular Cytokine Staining (ICS)"
        },
        {
            "endOffset": 37406,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0080",
            "sentence": "Intracellular Ag85A-specific IFN-\u03b3, TNF-\u03b1, IL-2 and IL-17 were examined in stimulated whole blood from volunteers in the two study groups B (MVA85A-IMX313) and C (MVA85A) at baseline, D7 and D168 post-vaccination.",
            "startOffset": 37193,
            "title": "Total whole blood intracellular cytokine response"
        },
        {
            "endOffset": 27556,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0040",
            "sentence": "Ag85A single pool of 66-peptides (Peptide Protein Research (PPR), UK), IMX313 peptides and C4bp (IMAXIO, France) were all used at a final concentration of 2 \u03bcg/ml.",
            "startOffset": 27393,
            "title": "Ex vivo IFN\u03b3 Enzyme-Linked ImmunoSpot (ELISpot) assay"
        },
        {
            "endOffset": 31628,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0055",
            "sentence": "All volunteers were randomised and vaccinated according to protocol, and so our analyses were per protocol.",
            "startOffset": 31521,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 40311,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0085",
            "sentence": "No differences were detected in MVA-specific IgG responses between the two study groups (Fig. 6B).",
            "startOffset": 40213,
            "title": "Serum IgG responses after MVA85A-IMX313 and MVA85A vaccination"
        },
        {
            "endOffset": 42289,
            "parents": [],
            "refoffsets": {
                "bib0170": {
                    "endOffset": 42288,
                    "startOffset": 42284
                }
            },
            "secId": "sec0090",
            "sentence": "In mice and non-human primates that had not received a prior BCG immunisation, two doses of MVA85A-IMX313 were required to demonstrate a significant enhancement of immune responses over MVA85A [12].",
            "startOffset": 42091,
            "title": "Discussion"
        },
        {
            "endOffset": 31839,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0055",
            "sentence": "Safety data was summarised by frequency and severity of AEs using descriptive statistics.",
            "startOffset": 31750,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 35811,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0075",
            "sentence": "There were no significant differences between the Ag85A ELISpot responses in the two groups B (MVA85A-IMX313) and C (MVA85A) at any time point post-vaccination, or in the overall Ag85A-specific IFN-\u03b3 response (AUC, p = 0.5059).",
            "startOffset": 35584,
            "title": "MVA85A and MVA85A-IMX313 induces mycobacteria-specific ex vivo IFN-\u03b3 ELISpot responses"
        },
        {
            "endOffset": 44870,
            "parents": [],
            "refoffsets": {
                "bib0160": {
                    "endOffset": 44769,
                    "startOffset": 44765
                }
            },
            "secId": "sec0090",
            "sentence": "Following the failure of MVA85A to enhance efficacy in BCG-vaccinated South African infants [10], there has been a refocussing of efforts to develop a diverse range of potent candidate TB vaccines.",
            "startOffset": 44673,
            "title": "Discussion"
        },
        {
            "endOffset": 22450,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "We undertook a phase I, randomised, open-label, first-in-human clinical trial in 30 BCG-vaccinated adults to assess the safety and immunogenicity of a candidate TB vaccine, MVA85A-IMX313.",
            "startOffset": 22263,
            "title": "Study design"
        },
        {
            "endOffset": 28569,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0045",
            "sentence": "Blood samples were stimulated with Ag85A peptides, or SEB (Sigma\u2013Aldrich), or left without stimulation as a negative control.",
            "startOffset": 28444,
            "title": "Whole Blood (WB) Intracellular Cytokine Staining (ICS)"
        },
        {
            "endOffset": 26953,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "Assignment of a causal relationship for AEs was conducted according to predefined criteria specified in the protocol.",
            "startOffset": 26836,
            "title": "Clinical procedures"
        },
        {
            "endOffset": 35398,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0075",
            "sentence": "Vaccination of BCG-primed UK adults with MVA85A-IMX313 or MVA85A, both at 5 \u00d7 107 pfu, induced a significant increase in Ag85A-specific IFN-\u03b3 responses that was durable up to 6 months following vaccination.",
            "startOffset": 35192,
            "title": "MVA85A and MVA85A-IMX313 induces mycobacteria-specific ex vivo IFN-\u03b3 ELISpot responses"
        },
        {
            "endOffset": 31498,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0050",
            "sentence": "A pool of Ag85A-positive sera was included in all plates.",
            "startOffset": 31441,
            "title": "Antibody Enzyme Linked Immunosorbent assay (ELISA)"
        },
        {
            "endOffset": 28769,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0045",
            "sentence": "\u03b1CD28 and \u03b1CD49d (BD) were used as co-stimulatory antibodies and samples were incubated at 37 \u00b0C/5% CO2 for 6 h. Following this, Brefeldin A (Sigma\u2013Aldrich) was added before a further 6 h incubation.",
            "startOffset": 28570,
            "title": "Whole Blood (WB) Intracellular Cytokine Staining (ICS)"
        },
        {
            "endOffset": 29243,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0045",
            "sentence": "Samples were acquired on LSRII (Becton Dickinson).",
            "startOffset": 29193,
            "title": "Whole Blood (WB) Intracellular Cytokine Staining (ICS)"
        },
        {
            "endOffset": 41855,
            "parents": [],
            "secId": "sec0090",
            "sentence": "At the peak time point 1 week post-vaccination both vaccines induced Ag85A-specific IFN-\u03b3 ELISpot responses that were not significantly different.",
            "startOffset": 41709,
            "title": "Discussion"
        },
        {
            "endOffset": 34178,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "There was one laboratory AE considered related to vaccination.",
            "startOffset": 34116,
            "title": "Vaccine safety"
        },
        {
            "endOffset": 20523,
            "parents": [],
            "secId": "sec0005",
            "sentence": "IMX313 is a small protein domain that self-assembles into a nanoparticle with seven identical chains.",
            "startOffset": 20422,
            "title": "Introduction"
        },
        {
            "endOffset": 32150,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0055",
            "sentence": "ELISpot, WB ICS and antibody response statistical analyses were performed using GraphPad Prism.",
            "startOffset": 32055,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 41088,
            "parents": [],
            "secId": "sec0090",
            "sentence": "The adverse event profiles of both MVA85A-IMX313 and MVA85A were similar and acceptable.",
            "startOffset": 41000,
            "title": "Discussion"
        },
        {
            "endOffset": 43386,
            "parents": [],
            "secId": "sec0090",
            "sentence": "The functional quality of these vaccine-induced CD4+ T cells was not enhanced by fusion to IMX313.",
            "startOffset": 43288,
            "title": "Discussion"
        },
        {
            "endOffset": 29447,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0045",
            "sentence": "Results are presented as percentages of antigen-specific cells producing cytokines minus responses measured in unstimulated cells.",
            "startOffset": 29317,
            "title": "Whole Blood (WB) Intracellular Cytokine Staining (ICS)"
        },
        {
            "endOffset": 20349,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Technologies that increase vaccine immunogenicity and effectiveness are critical to achieving this goal.",
            "startOffset": 20245,
            "title": "Introduction"
        },
        {
            "endOffset": 24540,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0025",
            "sentence": "Both vaccines were produced under Good Manufacturing Practice conditions (GMP) by IDT Biologika GmbH, Germany (IDT).",
            "startOffset": 24424,
            "title": "Vaccines"
        },
        {
            "endOffset": 30801,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0050",
            "sentence": "Plates were incubated at 37 \u00b0C for 1 h, then washed three times with PBS/T.",
            "startOffset": 30726,
            "title": "Antibody Enzyme Linked Immunosorbent assay (ELISA)"
        },
        {
            "endOffset": 28181,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0040",
            "sentence": "Staphylococcal enterotoxin B (Sigma) was used as a positive control and unstimulated PBMC were used as negative controls.",
            "startOffset": 28060,
            "title": "Ex vivo IFN\u03b3 Enzyme-Linked ImmunoSpot (ELISpot) assay"
        },
        {
            "endOffset": 40999,
            "parents": [],
            "secId": "sec0090",
            "sentence": "We demonstrated that this vaccine was well tolerated.",
            "startOffset": 40946,
            "title": "Discussion"
        },
        {
            "endOffset": 45332,
            "parents": [],
            "secId": "sec0095",
            "sentence": "Given the encouraging safety data in this study, future research optimising molecular proteins for further evaluation in recombinant viral vectors is warranted.",
            "startOffset": 45172,
            "title": "Conclusion"
        },
        {
            "endOffset": 21481,
            "parents": [],
            "refoffsets": {
                "bib0160": {
                    "endOffset": 21480,
                    "startOffset": 21476
                }
            },
            "secId": "sec0005",
            "sentence": "Despite this, in a South African phase IIb trial in 2797 South African, BCG-vaccinated infants, MVA85A was safe, but did not improve protective efficacy above the level achieved by BCG alone [10].",
            "startOffset": 21285,
            "title": "Introduction"
        },
        {
            "endOffset": 24200,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "The full inclusion and exclusion criteria are described in Supplementary Methods 1.",
            "startOffset": 24117,
            "title": "Participants"
        },
        {
            "endOffset": 30281,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0050",
            "sentence": "IgG subclasses levels to 85A or IMX313 antigen were determined in the sera by an indirect plate ELISA.",
            "startOffset": 30179,
            "title": "Antibody Enzyme Linked Immunosorbent assay (ELISA)"
        },
        {
            "endOffset": 31749,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0055",
            "sentence": "The primary study outcome was safety as assessed by the frequency and severity of vaccine-related local and systemic AEs.",
            "startOffset": 31628,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 31179,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0050",
            "sentence": "Plates were incubated for 1 h at 37 \u00b0C, then washed five times with PBS/T before the addition of 100 \u03bcL per well of TMB HRP Substrate for ELISA (UP664780, Interchim).",
            "startOffset": 31013,
            "title": "Antibody Enzyme Linked Immunosorbent assay (ELISA)"
        },
        {
            "endOffset": 29617,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0045",
            "sentence": "Data was analysed using FlowJo (Tree Star Inc., USA), and polyfunctional cytokine immune responses were analysed using Spice software (http://exon.niaid.nih.gov/spice/).",
            "startOffset": 29448,
            "title": "Whole Blood (WB) Intracellular Cytokine Staining (ICS)"
        },
        {
            "endOffset": 40560,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0085",
            "sentence": "As expected, these responses were not detected in the MVA85A alone group (C) (Fig. 6C).",
            "startOffset": 40473,
            "title": "Serum IgG responses after MVA85A-IMX313 and MVA85A vaccination"
        },
        {
            "endOffset": 19957,
            "parents": [],
            "secId": "sec0005",
            "sentence": "The only currently available licensed vaccine is Mycobacterium bovis (M. bovis) bacillus Calmette-Gu\u00e9rin (BCG).",
            "startOffset": 19846,
            "title": "Introduction"
        },
        {
            "endOffset": 27111,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "Blood for immunological assessment was taken at all follow-up visits and peripheral blood mononuclear cells (PBMC) and serum were isolated and cryopreserved.",
            "startOffset": 26954,
            "title": "Clinical procedures"
        },
        {
            "endOffset": 25056,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "The safety of the first volunteer was assessed and 48 h passed before the next two volunteers in group A were vaccinated.",
            "startOffset": 24935,
            "title": "Clinical procedures"
        },
        {
            "endOffset": 40058,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0085",
            "sentence": "Anti-MVA IgG was detected in both groups at D14 and D28 post-vaccination.",
            "startOffset": 39985,
            "title": "Serum IgG responses after MVA85A-IMX313 and MVA85A vaccination"
        },
        {
            "endOffset": 33232,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "The majority of AEs were mild in nature.",
            "startOffset": 33192,
            "title": "Vaccine safety"
        },
        {
            "endOffset": 45161,
            "parents": [],
            "secId": "sec0090",
            "sentence": "It is likely that multiple approaches will be required.",
            "startOffset": 45106,
            "title": "Discussion"
        },
        {
            "endOffset": 20802,
            "parents": [],
            "refoffsets": {
                "bib0140": {
                    "endOffset": 20801,
                    "startOffset": 20798
                }
            },
            "secId": "sec0005",
            "sentence": "In pre-clinical studies, IMX313 has an adjuvant-like effect when fused with protein antigens [6].",
            "startOffset": 20705,
            "title": "Introduction"
        },
        {
            "endOffset": 39909,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0085",
            "sentence": "Ag85A-specific IgG2 increased in the MVA85A-IMX313 group with a median OD 405 nm fold change of 1.355.",
            "startOffset": 39807,
            "title": "Serum IgG responses after MVA85A-IMX313 and MVA85A vaccination"
        },
        {
            "endOffset": 43463,
            "parents": [],
            "secId": "sec0090",
            "sentence": "We detected comparable increased levels of anti-85A IgG in both study groups.",
            "startOffset": 43386,
            "title": "Discussion"
        },
        {
            "endOffset": 30063,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "secId": "sec0050",
            "sentence": "Anti-vector IgG responses were measured to wild-type MVA (Vector Core Facility, Jenner Institute, Oxford), IMX313 (IMAXIO, France) and hC4bp proteins (provided by Anna Blom, Sweden).",
            "startOffset": 29881,
            "title": "Antibody Enzyme Linked Immunosorbent assay (ELISA)"
        },
        {
            "endOffset": 32646,
            "parents": [],
            "secId": "sec0060",
            "sentence": "The baseline demographics were similar between groups (Table 1).",
            "startOffset": 32582,
            "title": "Results"
        },
        {
            "endOffset": 20245,
            "parents": [],
            "secId": "sec0005",
            "sentence": "An improved TB vaccine is urgently required.",
            "startOffset": 20201,
            "title": "Introduction"
        },
        {
            "endOffset": 26571,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "Safety bloods (full blood count, urea and electrolytes, liver enzymes) were collected on D7 and D84 post-vaccination.",
            "startOffset": 26454,
            "title": "Clinical procedures"
        },
        {
            "endOffset": 32359,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0055",
            "sentence": "The Wilcoxon matched pairs signed rank test was used to detect differences between time points in the same group.",
            "startOffset": 32246,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 39084,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                },
                {
                    "id": "sec0070",
                    "title": "Vaccine immunogenicity"
                }
            ],
            "secId": "sec0080",
            "sentence": "No polyfunctional CD8+ T cells were detected.",
            "startOffset": 39039,
            "title": "Total whole blood intracellular cytokine response"
        },
        {
            "endOffset": 20421,
            "parents": [],
            "secId": "sec0005",
            "sentence": "One example is the immunogenicity-enhancing protein technology, IMX313.",
            "startOffset": 20350,
            "title": "Introduction"
        },
        {
            "endOffset": 22868,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "Recruitment took place at the Centre for Clinical Vaccinology and Tropical Medicine, Oxford, and the NIHR Wellcome Trust Clinical Research Facility, Birmingham.",
            "startOffset": 22708,
            "title": "Study design"
        },
        {
            "endOffset": 27392,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                },
                {
                    "id": "sec0035",
                    "title": "Immunological evaluations"
                }
            ],
            "refoffsets": {
                "bib0175": {
                    "endOffset": 27391,
                    "startOffset": 27387
                }
            },
            "secId": "sec0040",
            "sentence": "ELISpot assays were performed on freshly isolated PBMC, from all volunteers at screening or on day of vaccination and on days 7, 14, 28, 84 and 168 post-vaccination, as previously described [13].",
            "startOffset": 27197,
            "title": "Ex vivo IFN\u03b3 Enzyme-Linked ImmunoSpot (ELISpot) assay"
        },
        {
            "endOffset": 21659,
            "parents": [],
            "secId": "sec0005",
            "sentence": "The reasons for this could be manifold, but one hypothesis is that MVA85A elicited insufficient IFN-\u03b3-producing T helper (Th1) and/or IL-17-producing CD4+ (Th17) cell responses.",
            "startOffset": 21482,
            "title": "Introduction"
        },
        {
            "endOffset": 41374,
            "parents": [],
            "secId": "sec0090",
            "sentence": "The only severe systemic AEs considered possibly related to vaccination were in a group B volunteer who developed nausea, fatigue and malaise during a diarrhoeal illness that her family also became unwell with.",
            "startOffset": 41164,
            "title": "Discussion"
        },
        {
            "endOffset": 25274,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "Once all 6 volunteers in group A had been followed up for 14 days, the dose was escalated to 5 \u00d7 107 pfu.",
            "startOffset": 25169,
            "title": "Clinical procedures"
        },
        {
            "endOffset": 26160,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "Following vaccination and safety reviews at 30 and 60 min, all volunteers were followed up for a period of 6 months, with clinic visits at days 2, 7, 14, 28, 84 and 168.",
            "startOffset": 25991,
            "title": "Clinical procedures"
        },
        {
            "endOffset": 22040,
            "parents": [],
            "refoffsets": {
                "bib0165": {
                    "endOffset": 22039,
                    "startOffset": 22035
                }
            },
            "secId": "sec0005",
            "sentence": "In both mice and non-human primate studies IMX313 improved the immunogenicity of MVA85A [11].",
            "startOffset": 21947,
            "title": "Introduction"
        },
        {
            "endOffset": 25168,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "The remaining volunteers in group A were vaccinated once the Chief Investigator decided it was safe to proceed.",
            "startOffset": 25057,
            "title": "Clinical procedures"
        },
        {
            "endOffset": 33054,
            "parents": [
                {
                    "id": "sec0060",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "There was no statistical difference between group B and C (p = 0.5024).",
            "startOffset": 32983,
            "title": "Vaccine safety"
        }
    ],
    "docId": "S0264410X16001250",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": null,
                "first": "Alice",
                "initial": "A.",
                "last": "Minhinnick"
            },
            {
                "email": null,
                "first": "Iman",
                "initial": "I.",
                "last": "Satti"
            },
            {
                "email": null,
                "first": "Stephanie",
                "initial": "S.",
                "last": "Harris"
            },
            {
                "email": null,
                "first": "Morven",
                "initial": "M.",
                "last": "Wilkie"
            },
            {
                "email": null,
                "first": "Sharon",
                "initial": "S.",
                "last": "Sheehan"
            },
            {
                "email": null,
                "first": "Lisa",
                "initial": "L.",
                "last": "Stockdale"
            },
            {
                "email": null,
                "first": "Zita Rose Manjaly",
                "initial": "Z.R.M.",
                "last": "Thomas"
            },
            {
                "email": null,
                "first": "Raquel",
                "initial": "R.",
                "last": "Lopez-Ramon"
            },
            {
                "email": null,
                "first": "Ian",
                "initial": "I.",
                "last": "Poulton"
            },
            {
                "email": null,
                "first": "Alison",
                "initial": "A.",
                "last": "Lawrie"
            },
            {
                "email": null,
                "first": "Samantha",
                "initial": "S.",
                "last": "Vermaak"
            },
            {
                "email": null,
                "first": "Alexandre",
                "initial": "A.",
                "last": "Le Vert"
            },
            {
                "email": null,
                "first": "Judith",
                "initial": "J.",
                "last": "Del Campo"
            },
            {
                "email": null,
                "first": "Fergal",
                "initial": "F.",
                "last": "Hill"
            },
            {
                "email": null,
                "first": "Paul",
                "initial": "P.",
                "last": "Moss"
            },
            {
                "email": "helen.mcshane@ndm.ox.ac.uk",
                "first": "Helen",
                "initial": "H.",
                "last": "McShane"
            }
        ],
        "doi": "10.1016/j.vaccine.2016.01.062",
        "firstpage": "1412",
        "issn": "0264410X",
        "keywords": [
            "IMX313",
            "Immunogenicity",
            "MVA85A",
            "Tuberculosis",
            "Vaccine"
        ],
        "lastpage": "1421",
        "openaccess": "Full",
        "pub_year": 2016,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults"
    }
}